Tumor Suppressor Merlin Offers a New Therapeutic Strategy for HER2-Low Breast Cancer
Journal of Student-Scientists' Research · 25.10.2023
DOI: 10.13021/jssr2023.3916 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Student-Scientists' Research, erschienen am 25.10.2023. Verfasst von ANJU ADVANI und 8 weiteren Autor:innen.
Abstract (Originalsprache)
HER2 (human epidermal growth factor receptor 2) receptor is a membrane tyrosine kinase and when activated affects cell proliferation and survival. HER2 amplification is the primary pathway of HER2 overexpression and is a major driver of tumor development and progression in the subset of BCs. Currently there is an ongoing clinical revolution in the expanded use of HER2 directed therapies to include HER2-low patients. Greater than 60% of BCs are HER2-low. The tumor suppressor protein Merlin suppresses mitogenesis by blocking receptor tyrosine kinase signaling and arrests migration/invasion. It has been suggested that merlin interacts with mitochondria. We hypothesize that HER2-low BC cells, under the loss of functional Merlin due to oxidative stress causing mitochondrial fission by PINK1, will elevate HER2 signaling. This could dramatically alter HER2-low cell sensitivity to anti-HER2 directed therapy. When oxidative stress was applied to HER2+ cells, an increased level of phosphorylated HER2 (Y877) was found in the EVs. This connection of Merlin with mitochondrial remodeling constitutes a new source of strategies for preferentially increasing the sensitivity of HER2-low BC to HER2 directed therapies and provides a new molecular targeting axis for a large previously untreated cohort of BC patients.
Schlagwörter
Zitieren
APA
ADVANI, A., Hasanzadah, L., MATHEW, E., HUANG, L., Rojas, A. M., Gade, P. V., Howard, M. A., Liotta, & Lance (2023). Tumor Suppressor Merlin Offers a New Therapeutic Strategy for HER2-Low Breast Cancer. Journal of Student-Scientists' Research. https://doi.org/10.13021/jssr2023.3916
Vancouver
ADVANI A, Hasanzadah L, MATHEW E, HUANG L, Rojas AM, Gade PV, et al. Tumor Suppressor Merlin Offers a New Therapeutic Strategy for HER2-Low Breast Cancer. Journal of Student-Scientists' Research. 2023. doi:10.13021/jssr2023.3916
BibTeX
@article{ADVANI2023,
author = {ADVANI, ANJU and Hasanzadah, Layla and MATHEW, EMMA and HUANG, LINDA and Rojas, Angela M. and Gade, Purva V. and Howard, Marissa Ashton and Liotta and Lance},
title = {Tumor Suppressor Merlin Offers a New Therapeutic Strategy for HER2-Low Breast Cancer},
journal = {Journal of Student-Scientists' Research},
year = {2023},
doi = {10.13021/jssr2023.3916}
}
EUVIMED